NasoVAX

BIOLOGICAL2 trials

Sponsors

Altimmune, Inc.

Conditions

Coronavirus InfectionInfluenza

Phase 2

Single-ascending-dose Study of the Safety and Immunogenicity of NasoVAX

CompletedNCT03232567

Altimmune, Inc.Influenza

Start: 2017-09-18End: 2018-06-15Updated: 2024-04-30

NasoVAX in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19)

TerminatedNCT04442230

Altimmune, Inc.Coronavirus Infection

Start: 2020-10-10End: 2021-02-15Updated: 2022-04-04